Source link : https://www.newshealth.biz/health-news/ribociclib-reduces-risk-of-recurrence-for-high-risk-node-negative-breast-cancer/
The latest analysis from the phase III NATALEE trial demonstrated that adding ribociclib (Kisqali) to endocrine therapy improved rates of invasive disease-free survival (iDFS), distant recurrence-free survival, and distant disease-free survival in high-risk early breast cancer patients with node-negative disease. The findings were reported at the recent American Society of Clinical Oncology (ASCO) annual meeting. […]
Author : News Health
Publish date : 2024-07-01 16:07:13
Copyright for syndicated content belongs to the linked Source.
inHealth